| Old Articles: <Older 7391-7400 Newer> |
|---|
 |
The Motley Fool
April 29, 2011
Brandon Glenn |
Invacare Lifts Prices to Offset Rising Commodity, Freight Costs The price hikes didn't affect first-quarter results, but what about the rest of the year?   |
BusinessWeek
April 28, 2011
Ashlee Vance |
Pacific Biosciences' $600 Million Decoder Ring Pacific Biosciences' technology may finally fulfill the dream of gene sequencing. |
The Motley Fool
April 28, 2011
Brian Orelli |
1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix. |
The Motley Fool
April 28, 2011
Brian Orelli |
Celgene Gets No Love The market shrugs off a solid quarter. |
The Motley Fool
April 28, 2011
Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool
April 28, 2011
Brian Orelli |
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
April 27, 2011
Brian Orelli |
Don't Get Pumped Up About Pumping It In Medtronic and Eli Lilly team up against Parkinson's. |
The Motley Fool
April 27, 2011
Brian D. Pacampara |
Jazz Pharmaceuticals Shares Plunged then Recovered: What You Need to Know Shares of drug maker Jazz Pharmaceuticals suddenly plummeted 30% this morning only to quickly recover the majority of that loss. |
| <Older 7391-7400 Newer> Return to current articles. |
